Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bacterial Infections and Mycoses

  Free Subscription


Articles published in J Med Chem

Retrieve available abstracts of 37 articles:
HTML format



Single Articles


    November 2022
  1. GUO X, Yan T, Rao J, An Y, et al
    Novel Feleucin-K3-Derived Peptides Modified with Sulfono-gamma-AA Building Blocks Targeting Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus Infections.
    J Med Chem. 2022 Nov 9. doi: 10.1021/acs.jmedchem.2c01396.
    PubMed     Abstract available


  2. SAINI V, Mehta D, Gupta S, Kumar S, et al
    Targeting Vancomycin-Resistant Enterococci (VRE) Infections and Van Operon-Mediated Drug Resistance Using Dimeric Cholic Acid-Peptide Conjugates.
    J Med Chem. 2022 Nov 4. doi: 10.1021/acs.jmedchem.2c01293.
    PubMed     Abstract available


    October 2022
  3. MEIERS J, Rox K, Titz A
    Lectin-Targeted Prodrugs Activated by Pseudomonas aeruginosa for Self-Destructive Antibiotic Release.
    J Med Chem. 2022;65:13988-14014.
    PubMed     Abstract available


  4. KUBINSKI K, Maslyk M, Janeczko M, Goldeman W, et al
    Metallacarborane Derivatives as Innovative Anti-Candida albicans Agents.
    J Med Chem. 2022 Oct 11. doi: 10.1021/acs.jmedchem.2c01167.
    PubMed     Abstract available


    September 2022
  5. ZHANG W, Lun S, Wang SS, Cai YP, et al
    Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for Mycobacterium tuberculosis Treatment.
    J Med Chem. 2022 Sep 29. doi: 10.1021/acs.jmedchem.2c01064.
    PubMed     Abstract available


  6. ANG CW, Lee BM, Jackson CJ, Wang Y, et al
    Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
    J Med Chem. 2022 Sep 16. doi: 10.1021/acs.jmedchem.2c00972.
    PubMed     Abstract available


    August 2022
  7. LI L, Wu H, Zhu S, Ji Z, et al
    Discovery of Novel 7-Hydroxy-5-oxo-4,5-dihydrothieno[3,2-b]pyridine-6-carboxamide Derivatives with Potent and Selective Antifungal Activity against Cryptococcus Species.
    J Med Chem. 2022;65:11257-11269.
    PubMed     Abstract available


  8. HE T, Xu L, Hu Y, Tang X, et al
    Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.
    J Med Chem. 2022;65:10523-10533.
    PubMed     Abstract available


  9. LI C, Liu S, Dong B, Li C, et al
    Discovery and Mechanistic Study of Mycobacterium tuberculosis PafA Inhibitors.
    J Med Chem. 2022 Aug 4. doi: 10.1021/acs.jmedchem.2c00289.
    PubMed     Abstract available


  10. ZHAO H, Gao Y, Li W, Sheng L, et al
    Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-Resistant Tuberculosis.
    J Med Chem. 2022 Aug 1. doi: 10.1021/acs.jmedchem.2c00718.
    PubMed     Abstract available


    July 2022
  11. BEN HUR D, Kapach G, Wani NA, Kiper E, et al
    Antimicrobial Peptides against Multidrug-Resistant Pseudomonas aeruginosa Biofilm from Cystic Fibrosis Patients.
    J Med Chem. 2022;65:9050-9062.
    PubMed     Abstract available


    June 2022
  12. BURASTERO O, Defelipe LA, Gola G, Tateosian NL, et al
    Cosolvent Sites-Based Discovery of Mycobacterium Tuberculosis Protein Kinase G Inhibitors.
    J Med Chem. 2022 Jun 23. doi: 10.1021/acs.jmedchem.1c02012.
    PubMed     Abstract available


  13. ZHANG X, Wang M, Zhu X, Peng Y, et al
    Development of Lipo-gamma-AA Peptides as Potent Antifungal Agents.
    J Med Chem. 2022;65:8029-8039.
    PubMed     Abstract available


    May 2022
  14. WU Y, Jiang W, Cong Z, Chen K, et al
    An Effective Strategy to Develop Potent and Selective Antifungal Agents from Cell Penetrating Peptides in Tackling Drug-Resistant Invasive Fungal Infections.
    J Med Chem. 2022;65:7296-7311.
    PubMed     Abstract available


  15. FERNANDES GFS, Thompson AM, Castagnolo D, Denny WA, et al
    Tuberculosis Drug Discovery: Challenges and New Horizons.
    J Med Chem. 2022 May 25. doi: 10.1021/acs.jmedchem.2c00227.
    PubMed     Abstract available


  16. KOKOT M, Anderluh M, Hrast M, Minovski N, et al
    The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
    J Med Chem. 2022;65:6431-6440.
    PubMed     Abstract available


  17. NACLERIO GA, Abutaleb NS, Onyedibe KI, Karanja C, et al
    Mechanistic Studies and In Vivo Efficacy of an Oxadiazole-Containing Antibiotic.
    J Med Chem. 2022;65:6612-6630.
    PubMed     Abstract available


  18. LI W, Yun Z, Ji C, Tu J, et al
    Discovery of Novel Sertraline Derivatives as Potent Anti-Cryptococcus Agents.
    J Med Chem. 2022;65:6541-6554.
    PubMed     Abstract available


    April 2022
  19. GURVIC D, Leach AG, Zachariae U
    Data-Driven Derivation of Molecular Substructures That Enhance Drug Activity in Gram-Negative Bacteria.
    J Med Chem. 2022;65:6088-6099.
    PubMed     Abstract available


  20. LELLA M, Oh MW, Kuo SH, Lau GW, et al
    Attenuating the Streptococcus pneumoniae Competence Regulon Using Urea-Bridged Cyclic Dominant-Negative Competence-Stimulating Peptide Analogs.
    J Med Chem. 2022 Apr 22. doi: 10.1021/acs.jmedchem.2c00148.
    PubMed     Abstract available


  21. YIN W, Wu T, Liu L, Jiang H, et al
    Species-Selective Targeting of Fungal Hsp90: Design, Synthesis, and Evaluation of Novel 4,5-Diarylisoxazole Derivatives for the Combination Treatment of Azole-Resistant Candidiasis.
    J Med Chem. 2022;65:5539-5564.
    PubMed     Abstract available


    March 2022
  22. MA Z, He S, Yuan Y, Zhuang Z, et al
    Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
    J Med Chem. 2022;65:4481-4495.
    PubMed     Abstract available


  23. KOBAURI P, Galenkamp NS, Schulte AM, de Vries J, et al
    Hypothesis-Driven, Structure-Based Design in Photopharmacology: The Case of eDHFR Inhibitors.
    J Med Chem. 2022;65:4798-4817.
    PubMed     Abstract available


    February 2022
  24. ACEBRON-GARCIA-DE-EULATE M, Mayol-Llinas J, Holland MTO, Kim SY, et al
    Discovery of Novel Inhibitors of Uridine Diphosphate-N-Acetylenolpyruvylglucosamine Reductase (MurB) from Pseudomonas aeruginosa, an Opportunistic Infectious Agent Causing Death in Cystic Fibrosis Patients.
    J Med Chem. 2022;65:2149-2173.
    PubMed     Abstract available


  25. MODAK B, Girkar S, Narayan R, Kapoor S, et al
    Mycobacterial Membranes as Actionable Targets for Lipid-Centric Therapy in Tuberculosis.
    J Med Chem. 2022 Feb 8. doi: 10.1021/acs.jmedchem.1c01870.
    PubMed     Abstract available


    January 2022
  26. OTTAVI S, Scarry SM, Mosior J, Ling Y, et al
    In Vitro and In Vivo Inhibition of the Mycobacterium tuberculosis Phosphopantetheinyl Transferase PptT by Amidinoureas.
    J Med Chem. 2022 Jan 19. doi: 10.1021/acs.jmedchem.1c01565.
    PubMed     Abstract available


  27. SHYAM M, Verma H, Bhattacharje G, Mukherjee P, et al
    Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition.
    J Med Chem. 2022;65:234-256.
    PubMed     Abstract available


  28. HU Y, Li H, Qu R, He T, et al
    Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria In Vitro and In Vivo.
    J Med Chem. 2022;65:579-591.
    PubMed     Abstract available


  29. LIU J, Hou JS, Chang YQ, Peng LJ, et al
    New Pqs Quorum Sensing System Inhibitor as an Antibacterial Synergist against Multidrug-Resistant Pseudomonas aeruginosa.
    J Med Chem. 2022;65:688-709.
    PubMed     Abstract available


  30. LEE D, Lee E, Jang S, Kim K, et al
    Discovery of Mycobacterium tuberculosis Rv3364c-Derived Small Molecules as Potential Therapeutic Agents to Target SNX9 for Sepsis.
    J Med Chem. 2022 Jan 4. doi: 10.1021/acs.jmedchem.1c01551.
    PubMed     Abstract available


    November 2021
  31. TRAN W, Kusay AS, Hawkins PME, Cheung CY, et al
    Synthetic Sansanmycin Analogues as Potent Mycobacterium tuberculosis Translocase I Inhibitors.
    J Med Chem. 2021 Nov 30. doi: 10.1021/acs.jmedchem.1c01407.
    PubMed     Abstract available


  32. CHOI JW, Lee KT, Kim S, Lee YR, et al
    Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection.
    J Med Chem. 2021;64:15912-15935.
    PubMed     Abstract available


    October 2021
  33. PRATAP VERMA D, Ansari MM, Verma NK, Saroj J, et al
    Tandem Repeat of a Short Human Chemerin-Derived Peptide and Its Nontoxic d-Lysine-Containing Enantiomer Display Broad-Spectrum Antimicrobial and Antitubercular Activities.
    J Med Chem. 2021;64:15349-15366.
    PubMed     Abstract available


  34. FRIDIANTO KT, Li M, Hards K, Negatu DA, et al
    Functionalized Dioxonaphthoimidazoliums: A Redox Cycling Chemotype with Potent Bactericidal Activities against Mycobacterium tuberculosis.
    J Med Chem. 2021 Oct 27. doi: 10.1021/acs.jmedchem.1c01383.
    PubMed     Abstract available


  35. CHEN Z, Song K, Shang Y, Xiong Y, et al
    Selection and Identification of Novel Antibacterial Agents against Planktonic Growth and Biofilm Formation of Enterococcus faecalis.
    J Med Chem. 2021 Oct 16. doi: 10.1021/acs.jmedchem.1c00939.
    PubMed     Abstract available


    August 2021
  36. PEUKERT C, Langer LNB, Wegener SM, Tutov A, et al
    Optimization of Artificial Siderophores as (68)Ga-Complexed PET Tracers for In Vivo Imaging of Bacterial Infections.
    J Med Chem. 2021;64:12359-12378.
    PubMed     Abstract available


    July 2021
  37. KATO I, Ukai Y, Kondo N, Nozu K, et al
    Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.
    J Med Chem. 2021;64:10482-10496.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bacterial Infections and Mycoses is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: